Key take-aways
- In the RHEIA trial that compared treatments for severe aortic valve stenosis specifically in women, transcatheter aortic valve implantation (TAVI) was superior to surgical valve replacement for reducing death, stroke or rehospitalisation.
- The superiority of TAVI was driven by the lower rate of rehospitalisations and there were other benefits with TAVI including a shorter stay in hospital for the procedure compared with surgery.
- These results suggest that TAVI, with the balloon-expandable devices used in the trial, could be considered the preferred option to treat women with severe aortic stenosis.
London, United Kingdom – 31 August 2024: Transcatheter aortic valve implantation (TAVI) was superior to surgical aortic valve replacement for reducing death, stroke or rehospitalisation in women with severe aortic stenosis, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.1
“Limited data suggest that transcatheter, as compared with surgical, aortic valve replacement may be more effective in female than male patients. As most evidence is derived from subgroup analyses of large trials, we conducted a dedicated randomised trial to compare the safety and efficacy of TAVI vs. surgical replacement in women all-comers with severe symptomatic aortic stenosis. The RHEIA trial demonstrated not only the non-inferiority of TAVI but its superiority over surgery for improving outcomes, particularly reducing rehospitalisations,” explained one of the Principal Investigators, Professor Helene Eltchaninoff of the University Hospital of Rouen, France.
The prospective RHEIA trial recruited women all-comers with severe symptomatic aortic stenosis, with any (except prohibitive) surgical risk status, from 48 sites in 12 countries across Europe. They were randomised 1:1 to undergo either TAVI with a third-generation balloon-expandable system using transfemoral access or surgical aortic valve replacement and were followed up for 1 year. The primary composite endpoint was all-cause mortality, stroke and rehospitalisation for valve- or procedure-related symptoms or worsening heart failure at 1 year.
In total, 443 patients were randomised, with a mean age of 73 years. The mean Society of Thoracic Surgeons risk score was 2.1–2.2%.
The incidence of the primary composite endpoint was significantly lower in the TAVI group (8.9%) compared with the surgical group at 1 year (15.6%; hazard ratio [HR] 0.55; 95% confidence interval [CI] 0.34 to 0.88; p=0.03). The absolute event rate difference between the groups was −6.8% and the upper bound of the two-sided 95% CI met the criteria for both non-inferiority and superiority.
The significant reduction in the primary endpoint was predominantly driven by a reduction in rehospitalisation for valve- or procedure-related symptoms or worsening heart failure, which occurred in 4.8% in the TAVI group and 11.4% in the surgical group (difference −6.6%; 95% CI −11.9% to −1.4%; p=0.02). There was no significant difference in all-cause mortality or stroke.
TAVI was associated with a lower incidence of new-onset atrial fibrillation than surgery at 1 year (3.3% vs. 28.8%; p<0.001) and shorter median length of index hospital stay (4 days vs. 9 days), but higher rates of new permanent pacemaker implantation (8.8% vs. 2.9%; p=0.01) and mild paravalvular aortic regurgitation at 1 year (15.5% vs. 2.4%; p<0.001).
“In this first dedicated randomised TAVI trial in women, we were able to confirm its superiority over surgery, particularly with respect to reducing rehospitalisations. The added benefit of shorter index hospitalisations meant that TAVI treatment was able to reduce healthcare resource utilisation. Although we acknowledge the short post-intervention interval and longer follow-up will be useful, our findings suggest that in women with severe symptomatic aortic stenosis, TAVI using balloon-expandable devices could be considered the preferred therapy,” concluded Professor Eltchaninoff.
ENDS
Our mission: To reduce the burden of cardiovascular disease.